Sales for 3 Q were 15 MM and projected to be 25 MM in Q 4. Smells like a failed launch and need for a new CEO and sales director.
AND YOU NEED A NEW BRAIN.....SHORTY
Sentiment: Strong Buy
Its a slow launch due to contract situations. Everyone knows this. $300-500 million by 2014.
Would have thought the article about the comparability in terms of safety to Epogen from the New England journal of medicine would have helped today. As well as the positive article from Seeking Alpha today.
Contracts have to happen yes indeed. Contracts are fast becoming an excuse. This smells like Provenge to me.